Relmada Therapeutics (RLMD) Other Non-Current Assets (2014 - 2026)
Relmada Therapeutics (RLMD) reported Other Non-Current Assets of $19500.0 for Q1 2026, down 11.26% year-over-year from $21975.0 in Q1 2025, and little changed on a QoQ basis from $19500.0 in Q4 2025.
Relmada Therapeutics (RLMD) has 13 years of Other Non-Current Assets data on file, last reported at $19500.0 in Q1 2026.
- Quarterly Other Non-Current Assets fell 11.26% year-over-year to $19500.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19500.0 (down 11.26% YoY) and the FY2025 annual result came in at $19500.0, down 11.26% from the prior year.
- Other Non-Current Assets held at $19500.0 in Q1 2026 per RLMD's latest filing, from $19500.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $493452.0 in Q2 2023 and bottomed at $2000.0 in Q4 2022.
- The 5-year median for Other Non-Current Assets is $21975.0 (2024), against an average of $81891.5.
- The widest annual swing landed in 2023, when Other Non-Current Assets soared 2965.87%; it then plunged 95.55% in 2024.
- Tracing RLMD's Other Non-Current Assets over 5 years: stood at $2000.0 in 2022, then surged by 2056.25% to $43125.0 in 2023, then sank by 49.04% to $21975.0 in 2024, then fell by 11.26% to $19500.0 in 2025, then changed by 0.0% to $19500.0 in 2026.
- Per Business Quant, the three latest RLMD Other Non-Current Assets figures stand at $19500.0 (Q1 2026), $19500.0 (Q4 2025), and $21975.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | 19,500.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19,500.00 |
| Dec 31, 2025 | 19,500.00 |
| Sep 30, 2025 | 21,975.00 |
| Jun 30, 2025 | 21,975.00 |
| Mar 31, 2025 | 21,975.00 |
| Dec 31, 2024 | 21,975.00 |
| Sep 30, 2024 | 21,975.00 |
| Jun 30, 2024 | 53,625.00 |
| Mar 31, 2024 | 43,125.00 |
| Dec 31, 2023 | 43,125.00 |
| Sep 30, 2023 | 493,452.00 |
| Jun 30, 2023 | 493,452.00 |
| Mar 31, 2023 | 34,875.00 |
| Dec 31, 2022 | 2,000.00 |
| Sep 30, 2022 | 16,095.00 |
| Jun 30, 2022 | 35,238.00 |
| Mar 31, 2022 | 28,293.00 |
| Dec 31, 2021 | 28,293.00 |
| Sep 30, 2021 | 25,000.00 |
| Jun 30, 2021 | 25,000.00 |
| Mar 31, 2021 | 25,000.00 |
| Dec 31, 2020 | 25,000.00 |
| Sep 30, 2020 | 25,000.00 |
| Jun 30, 2020 | 25,000.00 |
| Mar 31, 2020 | 25,000.00 |
| Dec 31, 2019 | 25,000.00 |
| Sep 30, 2019 | 25,000.00 |
| Jun 30, 2019 | 25,000.00 |
| Mar 31, 2019 | 43,908.00 |
| Dec 31, 2018 | 18,908.00 |
| Sep 30, 2018 | 18,908.00 |
| Jun 30, 2018 | 24,788.00 |
| Mar 31, 2018 | 21,599.00 |
| Dec 31, 2017 | 21,961.00 |
| Sep 30, 2017 | 21,961.00 |
| Jun 30, 2017 | 21,961.00 |
| Mar 31, 2017 | 415,004.00 |
| Dec 31, 2016 | 414,811.00 |
| Sep 30, 2016 | 414,615.00 |
| Jun 30, 2016 | 390,000.00 |
| Mar 31, 2016 | 412,786.00 |
| Dec 31, 2015 | 412,786.00 |
| Sep 30, 2015 | 411,885.00 |
| Jun 30, 2015 | 400,825.00 |
| Mar 31, 2015 | 12,100.00 |
| Dec 31, 2014 | 12,100.00 |
| Sep 30, 2014 | 12,100.00 |
| Jun 30, 2014 | 12,100.00 |